Breaking News Instant updates and real-time market news.

TBIO

Translate Bio

$9.90

-0.1 (-1.00%)

, SYBX

Synlogic

$14.43

0.4 (2.85%)

04:55
10/03/18
10/03
04:55
10/03/18
04:55

Leerink to hold a roundtable

RARE Disease & Immuno-Oncology Roundtable will be held in New York on October 2-3.

TBIO

Translate Bio

$9.90

-0.1 (-1.00%)

SYBX

Synlogic

$14.43

0.4 (2.85%)

RETA

Reata Pharmaceuticals

$72.28

-3.61 (-4.76%)

FOLD

Amicus

$12.29

-0.51 (-3.98%)

NTLA

Intellia Therapeutics

$25.77

-1.37 (-5.05%)

ALXN

Alexion

$135.88

-1.03 (-0.75%)

BMRN

BioMarin

$99.02

0.44 (0.45%)

BOLD

Audentes Therapeutics

$34.34

-0.905 (-2.57%)

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 18

    Feb

TBIO Translate Bio
$9.90

-0.1 (-1.00%)

07/23/18
SBSH
07/23/18
INITIATION
Target $20
SBSH
Buy
Translate Bio initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Translate Bio with a Buy rating and $20 price target. The analyst views the company as a lower risk way to play the gene correction theme.
07/23/18
EVER
07/23/18
INITIATION
Target $25
EVER
Outperform
Translate Bio initiated with an Outperform at Evercore ISI
Evercore ISI initiated Translate Bio with an Outperform and $25 price target.
07/23/18
LEER
07/23/18
INITIATION
Target $24
LEER
Outperform
Translate Bio initiated with an Outperform at Leerink
Leerink analyst Geoffrey Porges initiated Translate Bio with an Outperform and $24 price target.
SYBX Synlogic
$14.43

0.4 (2.85%)

08/24/18
SBSH
08/24/18
UPGRADE
SBSH
Buy
Citi upgrades Synlogic to Buy after 28% pullback since July
Citi analyst Yigal Nochomovitz upgraded Synlogic to Buy from Neutral with an unchanged price target of $14. The stock has dropped 28% since July ahead of topline human proof-of-concept data expected by year-end for SYNB1020 in patients with elevated ammonia levels due to liver cirrhosis, Nochomovitz tells investors in a research note. The analyst, "for now," continues to assign a 15% probability of success for SYNB1020 in cirrhosis. However, he sees upside in the stock on positive data.
09/05/18
SBSH
09/05/18
NO CHANGE
Target $26
SBSH
Buy
Synlogic price target raised to $26 from $14 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Synlogic to $26 saying the Phase 1 data in healthy volunteers provides initial proof-of-concept for SYNB1618. Adverse events appeared manageable, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on Synlogic shares.
08/24/18
SBSH
08/24/18
UPGRADE
SBSH
Buy
Synlogic upgraded to Buy from Neutral at Citi
06/28/18
OPCO
06/28/18
INITIATION
Target $18
OPCO
Outperform
Synlogic initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started Synlogic with an Outperform rating and $18 price target, stating that its two lead products - SYNB1020 and SYNB1618 - could have clinical proof-of-concept data within the next 12 months and that the company's platform is well positioned to attract collaborations and partnerships.
RETA Reata Pharmaceuticals
$72.28

-3.61 (-4.76%)

09/26/18
SBSH
09/26/18
NO CHANGE
Target $185
SBSH
Buy
Citi sees 'very good entry point' for Reata Pharmaceuticals
Citi analyst Yigal Nochomovitz says he has more conviction in Reata Pharmaceuticals, his top SMID biotech pick, after the company announced final results from the IgA nephropathy and type 1 diabetic chronic kidney disease cohorts of PHOENIX, a Phase 2 study of bardoxolone methyl in patients with rare forms of CKD. He believes current share levels is a "very good entry point" and keeps a Buy rating on the shares with a $185 price target.
08/13/18
SBSH
08/13/18
NO CHANGE
Target $185
SBSH
Buy
Citi opens 90-day positive catalyst watch for Reata Pharmaceuticals
Citi analyst Yigal Nochomovitz opened a 90-day positive catalyst watch for his top pick Reata Pharmaceuticals ahead of the Q3 Phase 2 12-week data for lead asset bard in Type 1 diabetic chronic kidney disease. The analyst expects the data to be positive and sees potential share upside of 30%-40%. He has a Buy rating on Reata Pharmaceuticals with a $185 price target.
09/26/18
LTCO
09/26/18
NO CHANGE
Target $133
LTCO
Buy
Reata Pharmaceuticals price target raised to $133 from $102 at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan raised his price target for Reata Pharmaceuticals to $133 saying bardoxolone continues to consistently show improvement in kidney function in several rare forms of chronic kidney disease. The analyst continues to be impressed with the consistency of the efficacy results for bardoxolone and reiterates a Buy rating on Reata shares.
08/23/18
CANT
08/23/18
INITIATION
Target $90
CANT
Overweight
Reata Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night started Reata Pharmaceuticals with an Overweight rating and $90 price target. The analyst believes the company's lead candidates bardoxolone and omaveloxolone have a novel mechanism of actio and applicability in several diseases characterized by mitochondrial dysfunction, oxidative stress and chronic inflammation/fibrosis.
FOLD Amicus
$12.29

-0.51 (-3.98%)

10/04/17
BOFA
10/04/17
NO CHANGE
Target $20
BOFA
Buy
Amicus price target raised to $20 from $15 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised Amicus' price target to $20 from $15 saying the Phase 1/2 trial results of ATB200/AT2221 in Pompe disease were impressive. The analyst thinks the strong data justifies progression into pivotal trials and may result in an accelerated approval path. Ahmad rates Amicus a Buy.
04/11/18
JPMS
04/11/18
NO CHANGE
JPMS
Overweight
Amicus risk/reward favorable into regulatory update, says JPMorgan
JPMorgan analyst Anupam Rama notes that a regulatory update for Amicus Therapeutics' Pompe program is expected in Q2. The analyst continues to like the reward/risk profile of the shares going into the update. An accelerated approval path forward is "very much on the table," based on the strength of the Phase 1/2 data, Rama tells investors in a research note. He sees "more win scenarios than lose." The analyst believes Amicus shares can rally 30%-50% should an accelerated approval path forward emerge. Rama keeps an Overweight rating on Amicus with a $19 price target.
08/17/18
CHDN
08/17/18
DOWNGRADE
CHDN
Neutral
Amicus downgraded to Neutral from Buy at Chardan
05/08/18
JPMS
05/08/18
NO CHANGE
JPMS
Amicus lower on Pompe program commentary, says JPMorgan
JPMorgan analyst Anupam Rama attributes today's post-earnings weakness in shares of Amicus Therapeutics to "conservative commentary" on the call related to the Pompe program. The analyst, however, does not believe that the regulatory scenarios he outlined last month for the program have fundamentally changed. Nonetheless, Rama thinks commentary on the call, particularly on timing, was perceived as cautious. Amicus shares are down 7.5% to $13.49 in midday trading.
NTLA Intellia Therapeutics
$25.77

-1.37 (-5.05%)

07/18/18
JEFF
07/18/18
NO CHANGE
Target $40
JEFF
Buy
Study in Nature Biotech has limited readthrough to Intellia, says Jefferies
A new Nature Biotech publication highlights important safety points, but due to the methods/model systems used, the paper has limited readthrough to Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and Crispr Therapeutics (CRSP) programs advancing to the clinic, Jefferies analyst Maury Raycroft tells investors in a research note. The analyst believes the experiments used in the paper were not representative and may not have direct implications to current gene-editing clinical-directed strategies. The paper is another example of using a non-optimal model system with too many variables, Raycroft contends. He keeps a Buy rating on Intellia with a $40 price target.
09/21/18
RAJA
09/21/18
INITIATION
RAJA
Market Perform
Intellia Therapeutics initiated with a Market Perform at Raymond James
Raymond James analyst Steven Seedhouse initiated Intellia Therapeutics with a Market Perform saying he does not see a particular compelling reason to be either long or short shares in 2019 while initial trials play out elsewhere in the Crisp/Cas9 universe and expects the value proposition to become clearer as we approach initial IND in late 2019.
09/20/18
RAJA
09/20/18
INITIATION
RAJA
Market Perform
Intellia Therapeutics initiated with a Market Perform at Raymond James
08/24/18
OPCO
08/24/18
NO CHANGE
OPCO
Perform
Intellia presented positive ATTR preclinical results, says Oppenheimer
Oppenheimer analyst Leah Rush Cann says the high efficiency of Intellia Therapeutics' NTLA-1001 CRISPR/Cas9 guide and lipid nanoparticle delivery in preclinical mouse models and non-human primate models is "very encouraging" and supports her outlook for the company's success with its lead program for transthyretin amyloidosis. Following last night's data, the analyst's outlook for Intellia remains unchanged. She continues to expect an investigational new drug application for NTLA-1001 in ATTR by the end of 2019. Cann keeps a Perform rating on the shares.
ALXN Alexion
$135.88

-1.03 (-0.75%)

09/25/18
SBSH
09/25/18
NO CHANGE
Target $195
SBSH
Buy
Alexion price target raised to $195 from $173 at Citi
Citi analyst Robyn Karnauskas raised her price target for Alexion Pharmaceuticals to $195 following yesterday's Soliris data. The analyst says the data exceeded her expectations and that she expects approval in the neuromyelitis optica spectrum disorder indication. She now models 2025 NMO sales of $1.3B. Karnauskas keeps a Buy rating on Alexion shares.
09/26/18
PIPR
09/26/18
NO CHANGE
PIPR
Overweight
Piper remains buyer of Alexion after 'smart' Syntimmune acquisition
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Alexion Pharmaceuticals shares after the announced acquisition of Syntimmune. The analyst thinks investors will like additional evidence of deal execution from this management team, particularly following the Wilson acquisition earlier this year. He views the deal as "smart" and continues to like the setup for Alexion. Raymond keeps an Overweight rating on the name.
09/27/18
NOMU
09/27/18
NO CHANGE
Target $161
NOMU
Buy
Alexion acquisition bodes well for Argenx, says Nomura Instinet
Nomura Instinet analyst Christopher Marai believes Alexion Pharmaceuticals' (ALXN) acquisition of Syntimmune highlights potential demand for FcRn therapies by acquirers and bodes well for Argenx (ARGX). The analyst keeps a Buy rating on Argenx with a $161 price target.
09/28/18
LEHM
09/28/18
NO CHANGE
Target $175
LEHM
Overweight
Alexion price target raised to $175 from $165 at Barclays
Barclays analyst Geoff Meacham raised his price target for Alexion Pharmaceuticals to $175 saying this week's positive Phase 3 of Soliris data in neuromyelitis optica spectrum disorder "was a positive surprise for many and is the latest in a string of 'wins' for the company." The analyst thinks Alexion remains one of the more compelling names in biotech and he keeps an Overweight rating on the shares.
BMRN BioMarin
$99.02

0.44 (0.45%)

08/08/18
MZHO
08/08/18
NO CHANGE
Target $77
MZHO
Buy
Spark Therapeutics price target lowered to $77 from $91 at Mizuho
Mizuho analyst Difei Yang lowered her price target for Spark Therapeutics (ONCE) to $77 after the company provided an update on the SPK-8011 program for hemophilia A. While the latest data appears "somewhat mixed" with two out of the seven patients not maintaining Factor VIII level of at least 12%, Spark offered a reasonable explanation and proposal to address the issue in the upcoming Phase III trial that is scheduled to begin in Q4, Yang tells investors in a research note. The analyst finds it premature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN). Yang removed a takeover premium for Spark in her new price target but keeps a Buy rating on the shares.
09/06/18
PIPR
09/06/18
NO CHANGE
Target $120
PIPR
Overweight
Piper 'incrementally positive' on BioMarin after Valrox filing plans
Piper Jaffray analyst Christopher Raymond is "incrementally positive" on BioMarin shares after the company disclosed at a conference today that it plans to file for accelerated approval of Valrox, the company's hemophilia gene therapy, in the second half of 2019. The analyst notes this is a full year earlier than he currently models. Pulling Valrox forward by one year adds approximately $10 per share to the stock, Raymond tells investors in a research note. He keeps an Overweight rating on BioMarin with a $120 price target. The stock in early trading is up 2c to $96.62.
08/08/18
RHCO
08/08/18
NO CHANGE
Target $61
RHCO
Buy
Spark Therapeutics price target lowered to $61 from $102 at SunTrust
SunTrust analyst Edward Nash lowered his price target on Spark Therapeutics (ONCE) to $61, saying the company's SPK-8011 update has dimmed the outlook for its hemA program. Nash notes that while the FVIII activity reached the 30% threshold set by his physician consultants, it is below that of BioMarin (BMRN) BMN-270, adding the immune risk cannot be eliminated from the treatment. The analyst keeps his Buy rating on Spark Therapeutics, citing expectations of a gradual uptake of its Luxturna in 2018 with modeled commercial opportunity of $322M. Nash adds that Luxturna's commercial success should deepen the company's understanding of hemophilia and help differentiate its products from competitors.
10/01/18
CANT
10/01/18
INITIATION
Target $126
CANT
Overweight
BioMarin initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started BioMarin with an Overweight rating and $126 price target.
BOLD Audentes Therapeutics
$34.34

-0.905 (-2.57%)

08/21/18
SBSH
08/21/18
INITIATION
Target $40
SBSH
Neutral
Audentes Therapeutics initiated with a Neutral at Citi
Citi analyst Mohit Bansal initiated Audentes Therapeutics with Neutral and $40 price target saying valuation reflects much of the company's opportunities.
08/08/18
MZHO
08/08/18
UPGRADE
Target $45
MZHO
Buy
Audentes Therapeutics upgraded to Buy from Neutral at Mizuho
Mizuho analyst Difei Yang upgraded Audentes Therapeutics to Buy and raised her price target for the shares to $45 from $38. The analyst is "increasingly positive" on the company's AT-132 program. X-Linked myotubular myopathy patients treated so far with AT-132 continue to show significant improvements in neuromuscular and respiratory function, Yang tells investors in a research note.
09/06/18
RILY
09/06/18
INITIATION
Target $20
RILY
Sell
Audentes Therapeutics initiated with a Sell at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Audentes Therapeutics with a Sell rating and $20 price target. A modest market size opportunity and clinical data suggest the shares are overvalued, Kumar tells investors in a research note.
08/20/18
SBSH
08/20/18
INITIATION
Target $40
SBSH
Buy
Audentes Therapeutics initiated with a Buy at Citi
Citi initiated Audentes Therapeutics with a Buy and $40 price target.

TODAY'S FREE FLY STORIES

F

Ford

$8.34

-0.17 (-2.00%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CHMG

Chemung Financial

$41.99

-0.11 (-0.26%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Earnings
Chemung Financial reports Q4 EPS $1.18, consensus $1.04 »

Reports Q4 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.34

-0.17 (-2.00%)

18:03
01/23/19
01/23
18:03
01/23/19
18:03
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 2019 will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:01
01/23/19
01/23
18:01
01/23/19
18:01
Hot Stocks
Ford says 2018 auto EBIT benefited from improvement of market factors »

Says auto EBIT in 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:56
01/23/19
01/23
17:56
01/23/19
17:56
Hot Stocks
Henry Schein falls after saying it will not be key supplier to VCA,Pet Partners »

Shares of Henry Schein…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:51
01/23/19
01/23
17:51
01/23/19
17:51
Hot Stocks
Henry Schein will no longer be key supplier to VCA and Pet Partners »

Mars, Incorporated has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$44.40

0.22 (0.50%)

17:50
01/23/19
01/23
17:50
01/23/19
17:50
Hot Stocks
Hologic says FDA grants clearance for Aptima Mycoplasma genitalium assay »

Hologic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

F

Ford

$8.34

-0.17 (-2.00%)

17:41
01/23/19
01/23
17:41
01/23/19
17:41
Hot Stocks
Ford says 'optimistic' entering 2019 »

Says 2018 was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

RFL

Rafael Holdings

$16.90

-1.55 (-8.40%)

17:37
01/23/19
01/23
17:37
01/23/19
17:37
Hot Stocks
Rafael Holdings acquires majority stake in Rafael Pharma »

Rafael Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRDA

Crawford & Co.

$0.00

(0.00%)

, CRDB

Crawford & Company

$0.00

(0.00%)

17:34
01/23/19
01/23
17:34
01/23/19
17:34
Hot Stocks
Crawford & Co. to repurchase approximately 1.8M shares of CRD-A and CRD-B »

Crawford & Compan…

CRDA

Crawford & Co.

$0.00

(0.00%)

CRDB

Crawford & Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$31.93

0.13 (0.41%)

17:32
01/23/19
01/23
17:32
01/23/19
17:32
Hot Stocks
Teradyne up 6.5% after Q4 earnings beat, Q1 guidance, stock buyback »

Shares of Teradyne rose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    May

FHN

First Horizon

$14.59

0.07 (0.48%)

17:29
01/23/19
01/23
17:29
01/23/19
17:29
Syndicate
Breaking Syndicate news story on First Horizon »

First Horizon files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.34

-0.17 (-2.00%)

17:28
01/23/19
01/23
17:28
01/23/19
17:28
Hot Stocks
Ford sees longer-term revenue growth exceeding global GDP »

Sees longer-term adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

BA

Boeing

$358.81

0.9 (0.25%)

17:27
01/23/19
01/23
17:27
01/23/19
17:27
Periodicals
Boeing warns that shutdown will eventually impact business, CNBC reports »

According to a CNBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 28

    May

INBK

First Internet Bancorp

$24.22

-0.23 (-0.94%)

17:23
01/23/19
01/23
17:23
01/23/19
17:23
Earnings
First Internet Bancorp reports Q4 adj. EPS 53c, consensus 60c »

Reports Q4 CET1 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

INCY

Incyte

$75.20

-2.11 (-2.73%)

17:19
01/23/19
01/23
17:19
01/23/19
17:19
Upgrade
Incyte rating change  »

Incyte upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

HOMB

Home Bancshares

$18.39

0.15 (0.82%)

17:16
01/23/19
01/23
17:16
01/23/19
17:16
Hot Stocks
Home Bancshares raises quarterly dividend 9.1% to 12c per share »

Home BancShares, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

CVBF

CVB Financial

$22.08

-0.01 (-0.05%)

17:15
01/23/19
01/23
17:15
01/23/19
17:15
Earnings
CVB Financial reports Q4 EPS 31c, consensus 34c »

Reports Q4 NII $113.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

QSR

Restaurant Brands

$62.61

5.62 (9.86%)

17:15
01/23/19
01/23
17:15
01/23/19
17:15
Upgrade
Restaurant Brands rating change  »

Restaurant Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SPY

SPDR S&P 500 ETF Trust

$263.42

0.37 (0.14%)

, SPX

S&P 500

$0.00

(0.00%)

17:15
01/23/19
01/23
17:15
01/23/19
17:15
Periodicals
White House inquires about at-risk programs from shutdown, Wasington Post says »

Mick Mulvaney, the White…

SPY

SPDR S&P 500 ETF Trust

$263.42

0.37 (0.14%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSB

Franklin Financial Network

$27.73

-0.32 (-1.14%)

17:11
01/23/19
01/23
17:11
01/23/19
17:11
Earnings
Franklin Financial Network reports Q4 core EPS 61c, consensus 62c »

Net interest margin for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

  • 12

    Feb

  • 13

    Feb

TER

Teradyne

$31.93

0.13 (0.41%)

17:09
01/23/19
01/23
17:09
01/23/19
17:09
Hot Stocks
Breaking Hot Stocks news story on Teradyne »

Teradyne expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    May

TER

Teradyne

$31.93

0.13 (0.41%)

17:08
01/23/19
01/23
17:08
01/23/19
17:08
Earnings
Teradyne sees Q1 EPS 39c-47c, consensus 46c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    May

TER

Teradyne

$31.93

0.13 (0.41%)

17:07
01/23/19
01/23
17:07
01/23/19
17:07
Earnings
Teradyne reports Q4 EPS 63c, consensus 50c »

Reports Q4 revenue $520M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    May

AVA

Avista

$41.02

-0.145 (-0.35%)

17:06
01/23/19
01/23
17:06
01/23/19
17:06
Hot Stocks
Avista, Hydro One Limited terminate merger agreement »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.